

Corsaut, L., et al. 2021. Immunogenicity study of a *Streptococcus suis* autogenous vaccine in preparturient sows and evaluation of passive maternal immunity in piglets. *BMC Veterinary Research* 11:72.

Available: <https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-021-02774-4>

Fourie, Kezia R., et al. 2021. Evaluation of immunogenicity and protection mediated by *Lawsonia intracellularis* subunit vaccines. *Vet Immunol Immunopathol* 2021 May 7; 237.

Available: <https://www.sciencedirect.com/science/article/abs/pii/S016524272100074X>

Weaver, G., et al. 2021. Composition comprising antigens and a mucosal adjuvant and a method for using. U.S. Patent 10,918,711 B2. Issued February 16, 2021.

Available: <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=10,918,711.PN.&OS=PN/10,918,711&RS=PN/10,918,711>

Weaver, et al. 2021. Composition comprising antigens and a mucosal adjuvant and a method for using. U.S. Patent 11,000,585. Issued May 11, 2021.

Available: <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11,000,585.PN.&OS=PN/11,000,585&RS=PN/11,000,585>

Jauro, S. et al. 2020. Immunogenicity of non-living anthrax vaccine candidates in cattle and protective efficacy of immune sera in A/J mouse model compared to the Sterne live spore vaccine. *Pathogens* 9(7), 557.

Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400155/>

Hau, S., et al. 2020. Evaluation of the recombinant proteins RlpB and VacJ as a vaccine for protection against *Glässeria parasuis* in pigs. *Veterinary Research* 6:167.

Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252510/>

Ravichandran, S. et al. 2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. *Sci. Transl. Med.* 12 July.

Available: <https://stm.sciencemag.org/content/12/550/eabc3539>

Vrabilkova, A., et al. 2020. Chimeric VP1-PCV2bCap protein as antigen for construction of recombinant vaccine against porcine circovirus type 2. J of Immunol. May 1, 204 (1 Supplement) 167.36.

Available: https://www.jimmunol.org/content/204/1_Supplement/167.36.abstract

QI, Z-T, et al. 2020. Comparison of immunological efficacy and SIgA content of different part after immunization of two H9N2 AIV inactivated vaccines. Progress in veterinary medicine 41 (4): 22-26.

Abstract on Chinese website with no URL.

Oreskovic, Z., et al. 2019. Aspects of intradermal immunization with different adjuvants: The role of dendritic cells and Th1/Th2 response. PLOS ONE, February 11, 2019

Available: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211896>

Gupta, K., et al. 2019. Comparative evaluation of adjuvant effect of Emulsigen-D and CpG-ODN on immune response to inactivated FADV vaccine in broiler breeders. Proceedings of the 68th Poultry Disease Conference, April 2019, page 111.

Available: https://aaap.memberclicks.net/assets/WPDC/WPDC_2019_final.pdf

Weaver, G., et al. 2019. Composition comprising antigens and a mucosal adjuvant and a method for using. U.S. Patent 10,279,031 B2. Issued May 7, 2019.

Available: <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017196318>

Sarkar, I, et al. 2019. Selection of adjuvants targeting specific pathogens. Expert Review of Vaccines, Vol 18, No.5; 505-521.

Available: <https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1604231>

Walaa, S., et al. 2018. Using Emulsigen-D as recent adjuvant in trivalent foot and mouth disease vaccine. ARC Journal of Animal and Veterinary Sciences 4(4): 12-19.

Available: <https://www.arcjournals.org/journal-of-animal-and-veterinary-sciences/volume-4-issue-4/3>

Burkova, K., et al. 2018. Adjuvants for animal vaccines. 2018. Viral Immunology Jan/Feb 2018. Vol. 31. No. 1. 11-22.

Available: <https://www.liebertpub.com/doi/10.1089/vim.2017.0049>

Walaa, S., et al. 2018. Using Emulsigen-D as recent adjuvant in trivalent foot and mouth disease vaccine. Global Journal of Medical Research: G Veterinary Science and Veterinary Medicine Vol 1, 8 Issue, Version 1.

Available: <https://www.arcjournals.org/journal-of-animal-and-veterinary-sciences/volume-4-issue-4/3>

Brockmeier, S., et al. 2018. Use of proteins identified through a functional genomic screen to develop a protein subunit vaccine that provides significant protection against virulent *Streptococcus suis* in pigs. *Infect Immun.* Mar 86(3):

Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820948/>

Abente, C.J., et al. 2018. Comparison of adjuvanted-whole inactivated virus and live-attenuated vaccines against challenge with contemporary, antigenically distinct swine H3N2 influenza A viruses. *J. virol.* Online Sept 2018.

Available: <https://journals.asm.org/doi/10.1128/JVI.01323-18>

Lee, Sio-Young, et al. 2017. Rapid engineering of foot-and-mouth disease vaccine and challenge viruses. *J. Virol.* Aug 15;91(16)

Available: <https://journals.asm.org/doi/10.1128/JVI.00155-17>

Park, et al. 2016. Altered adjuvant of foot-and-mouth disease vaccine improves immune response and protection from virus challenge. *Trials in Vaccinology.* Vol 5, pages 97-104.

Available: <https://www.sciencedirect.com/science/article/pii/S1879437816300110>

Angelos, J., et al 2016. Systemic and ocular immune responses in cattle following intranasal vaccination with precipitated or partially solubilized recombinant *Moraxella bovis* cytotoxin adjuvanted with polyacrylic acid. *Am J Vet Res* Vol 77, No. 12.

Available: <https://pubmed.ncbi.nlm.nih.gov/27901388/>

Nišavic, J. 2016. Examination of the influence of different adjuvants on the immunogenicity of vaccines against parainfluenza 3 virus in cattle. *Veterinarski Glasnik*, January. 70(3-4): 99-110.

Available: <https://pdfs.semanticscholar.org/1fed/86d66fba403e554148aae43253c2543d784f.pdf?ga=2.69594771.224887077.1623948595-2050446882.1622677872>

McCaig, W., et al. 2016. Characterization and potential of outer membrane vesicles produced by *Haemophilus parasuis*. 2016. *PLOS ONE*. March 1.

Available: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149132>

Park, M-E, et al. 2014. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats. *Vaccine* 32 (2014); 5221-5227.

Available: <https://pubmed.ncbi.nlm.nih.gov/25066738/>

Angelos, J., et al. 2014. Ocular immune responses in steers following intranasal vaccination with recombinant *Moraxella bovis* cytotoxin adjuvanted with polyacrylic acid. *Clin. Vaccine Immunol* 21(2):181.

Available: <https://journals.asm.org/doi/full/10.1128/CVI.00699-13>

Parmeswaran, N., et al. 2014. The effect of the TRL9 ligand CpG-Deoxynucleotide on the protective immune response to alcelaphine herpes-1-mediated malignant catarrhal fever in cattle. *Veterinary Research* 5-59. Available: <https://veterinaryresearch.biomedcentral.com/articles/10.1186/1297-9716-45-59>

Garg, R., et al. 2014. DNA vaccination for rabies: Evaluation and preclinical safety and toxicology. *Trials in Vaccinology* 3, 73-80. Available: <https://www.sciencedirect.com/science/article/pii/S1879437814000084>

Peters, J. et al. 2012. Effects of immunization with natural and recombinant lysine decarboxylase on canine gingivitis development. *Vaccine*. ISSN: 0264-410X. Available: <https://pubmed.ncbi.nlm.nih.gov/22975025/>

Ellison, S. and Lindsey, D. 2012. Clinical and serum antibody responses of *S. neurona* infected horses treated with Decoquinatate and Levamisole. *Intern. J. Appl. Res. Vet. Med.* Vol10, No1. Available: <http://www.jarvm.com/articles/Vol10Iss2/Vol10%20Iss2Ellison.pdf>

Kaur, M. et al. 2010. Rabies DNA vaccine encoding lysomone-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. *FASEB J.* Jan;24(1):173-183. Available: <https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.09-138644>

Kalthoff, D., et al. 2010. Immunization and challenge experiments with a new modified live bovine herpesvirus type 1 marker vaccine prototype adjuvanted with a co-polymer. *Vaccine* 28(2010) 5871-5877. Available: <https://pubmed.ncbi.nlm.nih.gov/20600486/>

Baums, C.G., et al. 2010. Immunity of an autogenous *Streptococcus suis* bacterin in preparturient sows and their piglets in relation to protection after weaning. *Clinical and Vaccine Immunology*. October, p 1589-1597. Available: <https://pubmed.ncbi.nlm.nih.gov/20739502/>

Vincent, A., et al. 2010. Experimental inoculation of pigs with pandemic H1N1 2009 virus and HI cross-reactivity with contemporary swine influenza virus antisera. *Open Access Wiley Online Library*. Available: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1750-2659.2009.00121.x>

Alves, M. P., et al. 2009. Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs. *Clinical and Vaccine Immunology*. Aug. 2009, p1151-1157. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725537/>

Ellison, S. and Witonsky, S. 2009. Evidence that antibodies against recombinant SnSAG1 of *Sarcocystis neurona* merozoites are involved in infection and immunity in equine protozoal myeloencephalitis. *Can J. Vet Res.* July: 73(3): 176-183.

Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705071/>

Lin, B.C. et al. 2006. Ability of adjuvants to enhance the systemic antibody responses against H1N1 and H3N2 swine influenza viruses. *Proceedings of the American Association of Swine Veterinarians 2006*, 221-228.

Available: https://mvpadjuvants.com/wp-content/uploads/2017/09/Lin_2006.pdf

Turkstra, Johan, A., and Rob H. Meleon. 2006. Active immunization against gonadotropin-releasing hormone, an active tool to block fertility axis in mammals. *Veterinary Sciences Today* November.

Available: <http://dspace.library.uu.nl/handle/1874/7533>

Wedlock, D. N. et al. 2005. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and *Mycobacterium bovis* BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. *Infect Immun.* June: 73 (6):3540-3546.

Available: <https://journals.asm.org/doi/10.1128/IAI.73.6.3540-3546.2005>

Wedlock, D. N. et al. 2005. Vaccination of cattle with *Mycobacterium bovis* culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis. *Vet. Immunol Immunopathol.* June. 15;106(1-2):53-63.

Available: <https://pubmed.ncbi.nlm.nih.gov/15910992/>

Vordermeier, M., et al. 2005. Synthetic peptide vaccination in cattle: induction of strong cellular immune responses against peptides derived from the *Mycobacterium bovis* antigen. *Vaccine* 23 (2005) 4375-4384.

Available: <https://pubmed.ncbi.nlm.nih.gov/15908057/>

Oumouna, M. et al, 2005. Formulation with CpG Oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. *J. Virol.* Feb 79 (4) 2005. 2024-2032.

Available: <https://journals.asm.org/doi/10.1128/JVI.79.4.2024-2032.2005>

Finstad, C. et al. 2004. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. *Vaccine* 22: 1300-1313.

Available: <https://pubmed.ncbi.nlm.nih.gov/15003660/>

Ionannou X. P., et al. 2003. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. *Vaccine.* Oct 1;21 (27-30): 4368-4372.

Available: <https://pubmed.ncbi.nlm.nih.gov/14505919/>

Razauskas, M. 2002. Development and experimental assay of inactivated Salmonella and E. coli vaccine for pigs. Veterinarija Ir Zootechnika. T. 19(41). 29-32.

Available: <https://vetzoo.lsmuni.lt/data/vols/2002/19/en/ruzauskas.pdf>

Hurnik, D. 2002. The effect of vaccination and use of commercial immunostimulants on the prevalence of Postweaning Multisystemic Wasting Syndrome in a pig herd. PEI Pork. Dec 31, 2002.

Available: <https://www.thepigsite.com/articles/the-effect-of-vaccination-and-use-of-commercial-immunostimulants-on-the-prevalence-of-pmws-in-a-pig-herd>

Ioannou, X. P. 2002. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. Sept. 2002. P 9002-9010.

Available: <https://journals.asm.org/doi/10.1128/JVI.76.18.9002-9010.2002/>

Goethe, R. et al. 2001. A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction. Vaccine 19 ((2001) 966-975.

Available: <https://pubmed.ncbi.nlm.nih.gov/11115723/>

Beer, M. et al. 2000. A new inactivated BVDV genotype I and II vaccine. An immunization and challenge study with BVDV genotype I. Vet Microbiol 2000 Nov 15;77 (1-2):195-208.

Available: <https://www.sciencedirect.com/science/article/pii/S0378113500002765>

Andrianarivo, A. G. et al. 1999. Immunogenicity of a killed Neospora caninum tachyzoite preparation formulated with different adjuvants. Int J. Parasitol. Oct 29 (10): 1613-1625.

Available: <https://pubmed.ncbi.nlm.nih.gov/10608448/>



To speak with an adjuvant expert: 402.331.5106 or 800.856.4648

MVP270122GLB ©2022 Phibro Animal Health Corporation. MVP adjuvants and MVP adjuvants logo design are registered trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates.